Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.


Reynolds, Helen E, Chrdle, Ales, Egan, Deirdre, Chaponda, Mas, Else, Laura, Chiong, Justin ORCID: 0000-0001-8063-6399, Back, David J and Khoo, Saye H (2015) Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. The Journal of antimicrobial chemotherapy, 70 (2). pp. 550-554.

[img] Text
2014 Reynolds RifRal JAC.pdf - Unspecified
Access to this file is embargoed until Unspecified.
Download (217kB)

Abstract

This study suggests that rifampicin induction of raltegravir is comparable between daily and intermittent rifampicin. In the absence of definitive clinical efficacy data to suggest otherwise, doses of 800 mg of raltegravir twice daily with rifampicin thrice weekly are well tolerated and yield higher AUCs and comparable C12 when compared with raltegravir alone.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 03 Jun 2015 10:51
Last Modified: 17 Dec 2022 01:45
URI: https://livrepository.liverpool.ac.uk/id/eprint/2011758
CORE (COnnecting REpositories)